Smith & Nephew plc (SNN)

NYSE: SNN · Real-Time Price · USD
33.23
+0.78 (2.40%)
At close: Nov 7, 2025, 4:00 PM EST
33.18
-0.05 (-0.15%)
After-hours: Nov 7, 2025, 7:00 PM EST
2.40%
Market Cap14.14B
Revenue (ttm)5.94B
Net Income (ttm)491.00M
Shares Out 874.63M
EPS (ttm)0.56
PE Ratio28.79
Forward PE15.43
Dividend$0.73 (2.20%)
Ex-Dividend DateOct 3, 2025
Volume1,003,937
Open32.83
Previous Close32.45
Day's Range32.76 - 33.60
52-Week Range23.69 - 38.79
Beta0.67
AnalystsHold
Price Target33.50 (+0.81%)
Earnings DateOct 30, 2025

About SNN

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]

Sector Healthcare
IPO Date Nov 16, 1999
Employees 18,060
Stock Exchange NYSE
Ticker Symbol SNN
Full Company Profile

Financial Performance

In 2024, Smith & Nephew's revenue was $5.81 billion, an increase of 4.70% compared to the previous year's $5.55 billion. Earnings were $412.00 million, an increase of 56.65%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for SNN stock is "Hold." The 12-month stock price target is $33.5, which is an increase of 0.81% from the latest price.

Price Target
$33.5
(0.81% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Smith & Nephew plc (SNN) Q3 2025 Sales Call Transcript

Smith & Nephew plc ( SNN) Q3 2025 Sales Call November 6, 2025 3:30 AM EST Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Re...

2 days ago - Seeking Alpha

Smith & Nephew: Expensive Valuations And Muted Growth May Dampen Upcoming Q3 Earnings Release

Smith & Nephew plc maintains a 'Hold' rating due to valuation concerns and limited near-term upside despite recent operational improvements. Sequential growth across all business units and a 100 basis...

2 days ago - Seeking Alpha

Smith+Nephew comparative study1 shows  PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound thera...

11 days ago - GlobeNewsWire

UFC® and Smith+Nephew announce multi-year extension of partnership

Smith+Nephew to continue as UFC's Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world's premier mixed martial arts or...

16 days ago - GlobeNewsWire

Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention

Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound ...

5 weeks ago - GlobeNewsWire

Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty

Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the laun...

5 weeks ago - GlobeNewsWire

Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant an...

2 months ago - GlobeNewsWire

Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own...

2 months ago - GlobeNewsWire

Smith & Nephew: Doing Better And Still Offers Value

Smith & Nephew's interim results confirm solid progress, with revenue up 5% and strong cash flow growth, supporting my continued 'buy' rating. Dividend growth has resumed after years of stagnation, an...

3 months ago - Seeking Alpha

Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript

Smith & Nephew plc (NYSE:SNN) Q2 2025 Earnings Conference Call August 5, 2025 3:30 AM ET Company Participants Deepak S. Nath - CEO & Director John Terence Rogers - CFO & Executive Director Conference...

3 months ago - Seeking Alpha

Top 2 Health Care Stocks You May Want To Dump In Q3

As of Aug. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: STAA
3 months ago - Benzinga

Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint...

4 months ago - GlobeNewsWire

Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fractures

The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the l...

4 months ago - GlobeNewsWire

Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will r...

4 months ago - GlobeNewsWire

Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ev...

5 months ago - GlobeNewsWire

New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized ins...

5 months ago - GlobeNewsWire

Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* co...

5 months ago - GlobeNewsWire

Study shows patients treated with Smith+Nephew's CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

The CARTIHEAL Implant will be featured at the  Arthroscopy Association of North America Annual Meeting (AANA 2025) this week

6 months ago - GlobeNewsWire

Smith+Nephew to showcase its CORI™ Surgical System at surgical clinics across Germany, Austria and Switzerland

“CORI on Tour” will highlight the latest advancements in robotics-assisted surgery for hip and knee joint replacement Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today anno...

6 months ago - GlobeNewsWire

Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript

Smith & Nephew plc (NYSE:SNN) Q1 2025 Results Conference Call April 30, 2025 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer John Rogers - Chief Financial Officer Conference Cal...

6 months ago - Seeking Alpha

Smith & Nephew: Underappreciated Recovery With Strategic Upside

Smith & Nephew is undergoing a turnaround under CEO Deepak Nath, focusing on margin expansion and growth through surgical robotics and regenerative technologies. Despite trading at a discount to peers...

7 months ago - Seeking Alpha

Trump tariffs: these two European healthcare stocks face the highest US revenue exposure

Global financial markets are in turmoil this morning after the US President announced sweeping tariffs on several countries in a push to lower the nation's trade deficit. Trump's new tariffs are parti...

Other symbols: NVO
7 months ago - Invezz

Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Sur...

8 months ago - GlobeNewsWire

Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopae...

8 months ago - GlobeNewsWire

New report confirms Smith+Nephew's OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Regi...

8 months ago - GlobeNewsWire